SLU-PP-915

What it is & what research shows

Study example available

SLU-PP-915 is listed as a small molecule in the metabolism section of this catalog. Also indexed as SLUPP915. A source-verified explanation of its mechanism and uses has not yet been completed here; the catalog category is not evidence of benefit.

One selected study: SLU-PP-915, an orally active compound that activates energy-regulating ERR receptors, was tested for exercise-related effects. Preclinical experiments were reported. The abstract does not clearly specify the animals or sample size for the SLU-PP-915 experiments. A usable numeric dose was not reported in the abstract reviewed for this summary. The compound increased exercise distance and duration. Activity was retained with oral delivery after accounting for exposure. The abstract presents SLU-PP-915 as a research tool for further study; it does not establish clinical benefits in people. [2.1]

Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal. Read the study summary
Sources & reading scope

Evidence summarized on PED Evidence

1 completed summaries

0 human-study reports

0 randomized-trial candidates

0 safety-topic reports

These counts describe completed summaries on this site, not the size of the full literature. Publications can share participants; design labels are discovery metadata, not appraisals.

Filter, save and compare SLU-PP-915 studies →

Selected study reading notes

Source-linked summaries with studied methods. These are separate from the automated summary counts above and are not formal quality appraisals.

Animal

What makes SLU-PP-915 worth investigating alongside 332?

Demonstrated findings

A chemically distinct ERR agonist showed oral activity and enhanced aerobic exercise capacity in preclinical experiments.

What might this mean? · interpretation

Improved delivery makes sustained ERR modulation an interesting research possibility.

What might this mean, and what would change the interpretation?

Preclinical oral activity does not establish human oral exposure or clinical benefit, and does not make 915 interchangeable with 332.

What would clarify this: Human exposure and tolerability studies followed by functional endpoints.

Mechanism to possible human relevance
Working explanation
Oral preclinical activity could make sustained ERR modulation easier to investigate.
Possible human implication, hypothesis
Oral exposure and exercise-capacity endpoints are plausible human research questions.
Evidence that would support it
Demonstrated human exposure, acceptable tolerability and replicated functional improvement.
Evidence that would challenge it
Poor human exposure, limiting adverse effects, or no functional response despite target engagement.
Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Publication identity and preclinical findings checked against PMID 41421047. Full text was unavailable.

More about SLU-PP-915: identity, safety & reference details
Small moleculeMetabolism
Primary research area
Emerging research
Regulatory status
Research status varies
Evidence level
Evidence level not yet characterized
Primary mechanism
Mechanism not yet characterized
Study findings available · Coverage varies by section

Also known as SLUPP915

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Animal · Abstract reviewed

What makes SLU-PP-915 worth investigating alongside 332?

A chemically distinct ERR agonist showed oral activity and enhanced aerobic exercise capacity in preclinical experiments.

Limits: Preclinical oral activity does not establish human oral exposure or clinical benefit, and does not make 915 interchangeable with 332.

Open primary source · Read interpretation separately
Explore outcomes for this compound
Uses & research

Uses have not been independently checked for this profile. Browse the original studies to see the conditions and populations investigated.

Known half-life

No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.

Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits

A catalog entry does not establish effectiveness, safety or approval. Study findings and quality appraisal remain separate.

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

A compound-specific safety synthesis is not available here yet. Lack of listed adverse effects does not establish safety.

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: SLU-PP-915 · slupp915

Searchable names: SLUPP915

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Browse all studies

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…

SLU-PP-915 study summaries

Human-first reading order. Intervention candidates are distinguished from background mentions in the library.